Stock AnalizPrecigen, Inc. PGEN
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Precigen, Inc. (PGEN) is a healthcare company listed in the US with a market value of about $1.6B. In the twelve months to September 30, 2026 it had revenue of $157M and net income of $24M, a net margin of 15.6%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a P/E of 45.4, 5-year revenue growth of -21% a year, a 5-year average ROIC of -152%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 89% below the current price.
Score: 0.4 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $157M | $10M | $4M | $6M | $27M | $14M | $32M | $91M | $151M | $231M | $191M |
| Net income | $24M | -$251M | -$126M | -$96M | $28M | -$92M | -$171M | -$322M | -$509M | -$117M | -$187M |
| Free cash flow | -$74M | -$90M | -$77M | -$68M | -$70M | -$63M | -$85M | -$174M | -$166M | -$150M | -$81M |
| EPS (diluted) | $0.10 | $-1.37 | $-0.47 | $-0.39 | $0.14 | $-0.47 | $-1.02 | $-2.09 | $-3.93 | $-0.98 | $-1.58 |
| Net margin | 15.6% | -2588.2% | -3216.2% | -1540.6% | 105.2% | -646.0% | -533.0% | -355.3% | -336.9% | -50.7% | -97.7% |
| ROIC | — | -73.2% | -302.5% | -79.0% | — | — | — | -66.8% | -84.6% | -20.1% | -21.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $14.00, 208% above the current price; targets range from $12.00 to $18.00; the consensus rating is “Buy”; expected EPS is $0.25 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Precigen’s P/E ratio?
About 45.4, based on the last twelve months of diluted earnings per share (forward P/E about 7.9).
Is Precigen stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 89% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Precigen pay a dividend?
Not currently.
Is Precigen a good stock to buy?
We do not give buy or sell advice. Precigen scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.